PBLA:OTC-Panbela Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.2369

Change

0.00 (-0.04)%

Market Cap

USD 1.15M

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 34.32B
UCBJY UCB SA ADR

+2.03 (+2.31%)

USD 33.77B
UCBJF UCB SA

N/A

USD 33.01B
WXIBF WuXi Biologics

N/A

USD 12.07B
WXXWY WuXi Biologics (Cayman) Inc

-0.10 (-1.68%)

USD 12.07B
GNMSF Genmab A/S

+1.76 (+0.84%)

USD 12.01B
IVBIY IVBIY

N/A

USD 11.04B
AKESF Akeso, Inc.

-0.06 (-0.57%)

USD 9.60B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 9.28B
SBMFF Sino Biopharmaceutical Limited

+0.05 (+9.58%)

USD 8.94B

ETFs Containing PBLA

GREK Global X MSCI Greece ETF 4.28 % 0.59 %

+1.79 (+3.36%)

USD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.66% 31% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.66% 31% F 14% F
Trailing 12 Months  
Capital Gain -44.91% 43% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.91% 43% F 23% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1,279.67% 93% A 96% N/A
Dividend Return 1,279.67% 93% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8,077.20% 7% C- 3% F
Risk Adjusted Return 15.84% 72% C 55% F
Market Capitalization 1.15M 33% F 20% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector